

BNSSG Joint Formulary Group

To be held on 10th April 2018 9:30am-12:30pm
Conference Room, level 5, South Plaza

Agenda

- 1. Welcome, Apologies and Declaration of Interests** **9:30am**
- 2. Minutes of the meeting January 2018 and Matters arising** **9:35am**
- 3. NICE New Technology Appraisals published January, February and March 2017 – For information only** **9:40am**

Will be included in the BNSSG Joint Formulary once Implementation plans have been submitted and agreed within NICE TA Review Group

- 3.1** Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA 503)
- 3.2** Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA 502)
- 3.3** Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA 501)
- 3.4** Ceritinib for untreated ALK-positive non-small cell lung cancer (TA 500)
- 3.5** Glecaprevir-pibrentasvir for treating chronic hepatitis C (TA 499)
- 3.6** Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA 498)
- 3.7** Golimumab for treating non-radiographic axial spondyloarthritis (TA 497)
- 3.8** Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA 507)
- 3.9** Lesinurad for treating chronic hyperuricaemia in people with gout (TA 506)
- 3.10** Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA 505)
- 3.11** Pirfenidone for treating idiopathic pulmonary fibrosis (TA 504)
- 3.12** Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA 510)
- 3.13** Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA 509)
- 3.14** Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee (TA 508)

4. New Drug Requests (NDRs)

- 4.1 Apixaban for adult patients requiring anticoagulation following mitral valve repair and tissue mitral valve replacements, (unlicensed) **9.45am**
- 4.2 Fobumix Easyhaler (budesonide/formoterol) for treatment of asthma, *Angela Stinchcombe, Deputy Head of Medicines Management North Somerset.* **10.15am**

5. Shared Care Protocols/TLS Status

10.40am

- 5.1 Quinagolide TLS change (red to amber)
- 5.2 Testosterone undecanoate (Nedido) SCP (new)
- 5.3 Testosterone (Sustanon) SCP (new)
- 5.4 Azathioprine SCP up date
- 5.5 Hydroxychloroquine SCP up date
- 5.6 Riluzole SCP up date
- 5.7 Mondaflinil TLS change (red to amber) and SCP (new)
- 5.8 Levodopa, carbidopa and Entacapone combined tablet SCP up date to include Stanek®
- 5.9 Entacapone SCP up date
- 5.10 For information only;
- Apixaban amendment
 - Sevelamer SCP reviewed by specialist pharmacist.

6. Individual Funding Requests

- Nil **11.50am**

7. Items for Discussion

- Metolazone prescribing in primary care **11.55am**
- Fiasp

8. NDRs for May Meeting (no paperwork, for information only)

12.15pm

- Lecicarbon A suppository for chronic constipation
- Melatonin for sleep disturbance in lewy body dementia
- Adex gel for patients with dry skin conditions

9. AOB

12.20pm

Natasha Mogford

Interface Pharmacist BNSSG Formulary

April 2018

2018 meeting dates (all Tuesday meetings)

Date	Cut off for NDRs and SCPs	Time	Venue
16th January (AM)	12th December	9:30 to 12:30	South Plaza, Conference room
27th February (PM)	16th January	14:00 to 16:30	Southmead, Pharmacy meeting
10 th April (AM)	27 th February	9:30 to 12:30	South Plaza, Conference room
22 nd May (PM)	10 th April	14:00 to 16:30	Southmead, Pharmacy meeting
26 th June (AM)	22 nd May	9:30 to 12:30	South Plaza, Bevan room (6 th)
4 th September (PM)	26 th June	14:00 to 16:30	Southmead, Pharmacy meeting
16 th October (AM)	4 th September	9:30 to 12:30	South Plaza, Conference room
27 th November (PM)	16 th October	14:00 to 16:30	Southmead, Pharmacy meeting room